Close Menu

lawsuit

Boram Pharm claims Life Tech's baculovirus expression system infringes its patent.

The settlement, which will be funded by insurance proceeds, relates to a lawsuit filed in November by Sequenom's shareholders alleging mishandling of data surrounding the company's SEQureDx test.

The suit, filed by Alnylam and Max Planck against the University of Massachusetts, MIT, and the Whitehead Institute for Biomedical Research, is set to go to trial Feb. 22.

GE Healthcare charges in its complaint that kits and instruments sold by Beckman Coulter Genomics based on the Agencourt Solid Phase Reversible Immobilization, or SPRI, technology "contain instructions to use the products in a manner that infringes one or more claims of the '231 and/or '946 patents."

CombiMatrix hopes to soon collect on a $36 million judgment in favor of the firm.

The complaint alleges breach of fiduciary duties against a number of current and ex-officials, and levels charges of insider stock trading against one of the former officials.

"The widespread use of gene sequence information as the foundation for biomedical research means that resolution of these issues will have far-reaching implications, not only for gene-based health care and the health of millions of women facing the specter of breast cancer, but also for the future course of biomedical research," the NY Southern District Court said in an opinion explaining the reasons for denying Myriad’s motion to dismiss ACLU’s challenge to its patents covering BRCA genes associated with hereditary breast and ovarian cancer.

A US district court decided this week that the lawsuit challenging the legality and constitutionality of BRCA gene patents owned by the University of Utah and exclusively licensed to Myriad has sufficient merit to be heard.

Xenomics is seeking up to $300 million in damages and the termination of its licensing deal with Sequenom.

The suit is the second that Life Tech has filed in as many weeks. It is also the second suit filed recently claiming that Illumina's Genome Analyzer infringes DNA amplification IP.

Pages

Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.

The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.

Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.

In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.